Editas Medicine (EDIT) Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Revenue data on file, last reported at $7.5 million in Q3 2025.

• Revenue for Q3 2025 came in at $7.5 million, up 12265.57% year-over-year; the trailing twelve-month figure through Sep 2025 was $46.4 million (down 24.9% YoY), and the FY2024 annual result was $32.3 million, down 58.64% from the prior year.
• Revenue rose to $7.5 million in Q3 2025 per EDIT's latest filing, from $3.6 million in the prior quarter.
• Over five years, Revenue peaked at $60.0 million in Q4 2023 and troughed at $42000.0 in Q3 2022.
• A 5-year average of $9.0 million and a median of $6.2 million in 2021 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue plunged 99.32% in 2022, then jumped 12604.76% in 2023.
• A 5-year view of Revenue shows it stood at $12.5 million in 2021, then tumbled by 47.58% to $6.5 million in 2022, then soared by 818.74% to $60.0 million in 2023, then plunged by 49.03% to $30.6 million in 2024, then slumped by 75.35% to $7.5 million in 2025.
• Business Quant data shows EDIT's Revenue at $7.5 million in Q3 2025, $3.6 million in Q2 2025, and $4.7 million in Q1 2025.